{"id":"NCT02694978","sponsor":"AMAG Pharmaceuticals, Inc.","briefTitle":"A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)","officialTitle":"A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-29","primaryCompletion":"2017-01-16","completion":"2017-07-17","firstPosted":"2016-03-01","resultsPosted":"2018-06-11","lastUpdate":"2023-07-25"},"enrollment":2014,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Iron Deficiency Anemia"],"interventions":[{"type":"DRUG","name":"Ferumoxytol","otherNames":["Feraheme"]},{"type":"DRUG","name":"FCM","otherNames":["Injectafer, Ferinject"]}],"arms":[{"label":"Ferumoxytol","type":"EXPERIMENTAL"},{"label":"FCM","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the safety of 1.020 grams (g) of intravenous (IV) ferumoxytol compared to 1.500 g of IV ferric carboxymaltose (FCM).","primaryOutcome":{"measure":"Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension","timeFrame":"Day 1 (after first dosing) through Week 5","effectByArm":[{"arm":"Ferumoxytol","deltaMin":3,"sd":null},{"arm":"Ferric Carboxymaltose (FCM)","deltaMin":6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":127,"countries":["United States","Canada","Hungary","Latvia","Lithuania","Poland","Puerto Rico"]},"refs":{"pmids":["29417614","29033620","30518682"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":997},"commonTop":["Headache","Nausea","Fatigue","Dizziness","Diarrhoea"]}}